Trading of Zogenix Common Stock Halted
07 déc. 2012 07h01 HE
|
Zogenix
FDA Advisory Committee Reviewing Zohydro™ ER New Drug Application
Zogenix to Host Conference Call at 6:30 pm ET Today
SAN DIEGO, Dec. 7, 2012 (GLOBE NEWSWIRE) -- Zogenix, Inc....
Zogenix Appoints New Chief Commercial Officer
26 nov. 2012 07h30 HE
|
Zogenix
SAN DIEGO, Nov. 26, 2012 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and...
Zogenix to Present at the 24th Annual Piper Jaffray Healthcare Conference
15 nov. 2012 08h00 HE
|
Zogenix
SAN DIEGO, Nov. 15, 2012 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and...
Preliminary Findings From Rheumatoid Arthritis Patient Survey Reveal Strong Interest in Needle-Free Self-Injection
13 nov. 2012 07h00 HE
|
Zogenix
COLUMBUS, Ohio and SAN DIEGO, Nov. 13, 2012 (GLOBE NEWSWIRE) -- Battelle, the world's largest independent research and development organization and Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical...
Zogenix Reports Third Quarter 2012 Financial Results
08 nov. 2012 16h01 HE
|
Zogenix
Growth Continues in Product Sales and Pipeline Remains on Track
Conference Call and Webcast Today, November 8th, at 4:30 p.m. ET
SUMAVEL® DosePro® (sumatriptan injection) Third...
Zogenix Announces FDA Advisory Committee Review of Zohydro(TM) ER for the Management of Chronic Pain
08 nov. 2012 09h25 HE
|
Zogenix
SAN DIEGO, Nov. 8, 2012 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and...
Zogenix Announces Conference Call and Webcast to Present Third Quarter 2012 Financial Results
25 oct. 2012 08h00 HE
|
Zogenix
SAN DIEGO, Oct. 25, 2012 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and...
Zogenix to Present New Case Study Highlighting Successful Repositioning of Injectable Sumatriptan for Migraine With a Novel Needle-Free Delivery Technology
23 oct. 2012 08h01 HE
|
Zogenix
SAN DIEGO, Oct. 23, 2012 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and...
Zogenix Announces Availability of New Resources for Migraine Sufferers at www.SUMAVELDosePro.com to Support National Pain Awareness Month
27 sept. 2012 08h00 HE
|
Zogenix
SAN DIEGO, Sept. 27, 2012 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and...
Zogenix to Present at Stifel Nicolaus 2012 Healthcare Conference
30 août 2012 16h30 HE
|
Zogenix
SAN DIEGO, Aug. 30, 2012 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and...